FDA
-
-
-
-
-
-
-
AMGEN's Repatha shows 29% cardiovascular event reduction in diabetes study
-
-
-
-
-
-
-
AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
-
-
-
-
-
-
-
Amgen’s Tavneos Tied to Deaths, Liver Injury - FDA
-
-
-
-
-
-
-
Here's the list of top biotech stocks to own for 2026
-
-
-
-
-
-
-
AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
-
-
-
-
-
-
-
Amgen's Repatha reduces cardiovascular events in prevention study
-
-
-
-
-
-
-
Amgen and Kyowa Kirin report one-year rocatinlimab safety data
-
331,394 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

